KRAS mutation status concordance between the primary tumor and the corresponding metastasis in patients with rectal cancer
Introduction Oncogenic mutation within the KRAS gene represents a negative predictor for treatment response to anti-epidermal growth factor receptor (EGFR) in patients with colorectal cancer. Recently, we have shown no relevant heterogeneity for KRAS mutation status within and between pre- and postt...
Main Authors: | Peter Jo, Markus Bernhardt, Manuel Nietert, Alexander König, Azadeh Azizian, Markus A. Schirmer, Marian Grade, Julia Kitz, Kirsten Reuter-Jessen, Michael Ghadimi, Philipp Ströbel, Hans-Ulrich Schildhaus, Jochen Gaedcke, Sumitra Deb |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529221/?tool=EBI |
Similar Items
-
KRAS mutation status concordance between the primary tumor and the corresponding metastasis in patients with rectal cancer.
by: Peter Jo, et al.
Published: (2020-01-01) -
Heterogeneity of KRAS Mutation Status in Rectal Cancer.
by: Peter Jo, et al.
Published: (2016-01-01) -
Prognostic Value of MicroRNAs in Preoperative Treated Rectal Cancer
by: Azadeh Azizian, et al.
Published: (2016-04-01) -
Epigenome Mapping Identifies Tumor-Specific Gene Expression in Primary Rectal Cancer
by: Hannah Flebbe, et al.
Published: (2019-08-01) -
Diameter of Superior Rectal Vein – CT Predictor of KRAS Mutation in Rectal Carcinoma
by: Song C, et al.
Published: (2020-10-01)